Formycon/Fresenius Kabi and Samsung Bioepis Settlements with J&J and Janssen Biotech regarding Ustekinumab
LexBlog IP
AUGUST 16, 2023
In February 2023, Formycon announced its entry into a global license agreement with Fresenius Kabi to commercialize FYB202 in key global markets after successful regulatory approvals. According to the press release, Formycon plans to submit a biologics license application later in 2023 to seek regulatory approval for FBY202.
Let's personalize your content